Strong American Results in Female Sexual Desire Drug
/Note: America’s FDA did not approve flibanserin’s forward movement in June 2010.
Are American daisy and violet women on their way to becoming erotic tulips? This sexy flower, once traded at exorbitant prices on Amsterdam’s money exchanges as priceless, may be a good way to envision an American woman taking Boehringer’s new female desire pill.
Women who took Boehringer Ingelheim GmbH’s desire drug pill, known as flibanserin, reported 22 percent more “satisfying sexual events” than those given a placebo in two clinical tests of 1,378 patients, according to abstracts released today at the European Society for Sexual Medicine annual meeting in Lyon, France. via Bloomberg News
See our earlier story Can Any Female Desire Drug Make Sexy Orchids From Pure Daisies?
Boehringer says it will move to market the drug in the US and Europe. The findings show women who took the drug had more sex, wanted more sex and experienced less distress related to lack of desire.
Reading the initial Bloomberg update: Boehringer’s Desire Drug Boosts Lust, Improves Sex, the North American results are the most interesting:
1. The placebo affect also worked. After taking the drug for six months, North American women taking the placebo reported 3.7 satisfying sex acts each month, compared to 2.7 acts during the baseline period.
2. The North American women taking 100 milligrams of flibanserin nightly reported an average of 4.5 satisfying sex acts per month, up from 2.8 acts during the four-week base line test period.
The Orchid test in Europe failed to deliver more satisfying sexual events, though women reported increased desire. A lower-dose version called Dahlia was ineffective.
Women in the study were premenopausal women treated for 24 weeks and were required to be a “stable, communicative, monogamous, heterosexual” relationship for one year. Anyone having secondary problems with arousal or orgams were excluded from the story, as well as those with any psychological or psychiatric history that could diminish ability to orgasm or experience sexual desire. Members of the study were not taking any medications that could diminish sexual function.
A sexual event didn’t necessarily result in orgasm.
A third of the women in the study dropped out for multiple reasons including expressed side affects of dizziness, nausea, drowsiness and insomnia. The drug takes three to six weeks to have an effect.
The choice of Violet and Daisy for American women and Orchid for Europe is no accident, in my opinion. Reading these results confirms everything that I know about American women, who are culturally more ambivalent about the sexuality.
Violets only appear to be innocent and nonsexual from afar. Study them closely, and you find far more voluptuousness revealed that any home gardener thought possible. The same can be said of women.
I have many questions about the research and have forwarded them on to Bloomberg News. Anne